Depomed — Proxy Contest (May 2016)
10 slides from Depomed's proxy contest presentation, May 4, 2016
Slide 1: Sohn Investment Conference
Sohn Investment Conference May 4, 2016
Slide 2: Overview of Depomed, Inc.
Overview of Depomed, Inc. Depomed, Inc. (the “Company”, “Depomed” or “DEPO”) is a specialty pharmaceutical company focused on pain and other central nervous system conditions. Headquartered in Newark, CA, Depomed has ~500 employees, including a sales force of ~300 professionals. In 2015, Depomed
Slide 3: Valuable Pain Franchise
Valuable Pain Franchise NUCYNTA ER GRALISE CAMBIA LAZANDA $175M $140M $60M $25M $150M $120M +27% CAGR +82% CAGR +43% CAGR $20M +155% CAGR $45M $125M $100M $15M $100M $80M $30M $75M $60M $10M $50M $40M $15M $5M $25M $20M $0M $0M $0M $0M 2012 2013 2014 2015 2012 2013 2014 2015 2012 2013 2014 2015 2012
Slide 4: Operational Inefficiencies
Operational Inefficiencies Concerns with the Company’s Research & Development Spending We have concerns about the Company’s development program for cebranopadol, given the compound’s storied past, mixed results in Phase 2 clinical trials, and Depomed’s lack of experience with Phase 3 clinical prog
Slide 5: Potential Value to an Acquirer
Potential Value to an Acquirer We believe Depomed could be extremely attractive to numerous potential acquirers, given operating, financial, and tax synergies. $3.00 >$120 Million of Potential Improvements $2.50 $1.03 $2.00 $1.50 $0.22 $0.22 $2.72 $1.00 $1.69 $1.25 $0.50 $0.00 Mgmt 2016 EPS Operatio
Slide 6: Depomed Trading History
Depomed Trading History $35.00 HZNP Offer Price 55%(1) stock decline since rejecting offer of $33.00 per share $30.00 $25.00 April 7, 2016: Starboard files 13-D $20.00 July 7, 2015: Horizon initial offer of $29.25 $15.00 $10.00 Horizon offered $33.00 per share, but Depomed failed to engage (1) From
Slide 7: Bylaw Amendments
Bylaw Amendments Following Horizon’s offer, Depomed amended its bylaws, which significantly undermined the rights of its shareholders. Rather than engage and negotiate with Horizon in an attempt to maximize value for shareholders, Depomed adopted bylaw amendments, as well as a 10% poison pill righ
Slide 8: Recent Proxy Filing
Recent Proxy Filing We believe that management and the Board were using the Reincorporation Proposal as a tactic to further entrench themselves. Depomed recently filed preliminary proxy materials for the upcoming annual meeting with a proposal to change the Company’s state of incorporation from CA
Slide 9: Summary
Summary We believe that Depomed is deeply undervalued and that significant opportunities exist to create value. Depomed has a portfolio of unique, high-quality pain products with an attractive and durable growth profile. We believe that opportunities exist to improve capital deployment, rational
Slide 10: Starboard Value disclaimer
THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT DOES NOT HAVE REGARD TO THE SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, SUITABILITY, OR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKEN AS ADVICE ON THE MERIT